Apixaban + Warfarin
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transient Ischemic Attack
Conditions
Transient Ischemic Attack, Stroke, Atrial Fibrillation
Trial Timeline
Apr 1, 2015 → Jun 1, 2019
NCT ID
NCT02283294About Apixaban + Warfarin
Apixaban + Warfarin is a phase 3 stage product being developed by Bristol Myers Squibb for Transient Ischemic Attack. The current trial status is completed. This product is registered under clinical trial identifier NCT02283294. Target conditions include Transient Ischemic Attack, Stroke, Atrial Fibrillation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02942407 | Approved | Completed |
| NCT02889562 | Phase 2/3 | Completed |
| NCT02450682 | Phase 2 | Withdrawn |
| NCT02283294 | Phase 3 | Completed |
| NCT02295475 | Approved | Completed |
Competing Products
10 competing products in Transient Ischemic Attack
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - Tablets | Eli Lilly | Phase 1 | 33 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Gabapentin | Pfizer | Phase 3 | 76 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 76 |
| Milvexian + Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Levosimendan + Placebo | Orion Corporation | Phase 2 | 49 |